Treatment Protocol for Pancreatitis in Dogs

Overview

1. Identify and Address Underlying Causes

• Dietary indiscretion / high-fat meal - dietary correction
• Hypertriglyceridemia - low-fat diet, sometimes gemfibrozil or omega-3 fatty acids; especially in Schnauzers, Cavalier King Charles Spaniels, Poodles, Cocker Spaniels (SPINK gene mutation implicated in Schnauzers)
• Hypercalcemia - treat the underlying cause (hyperparathyroidism, vitamin D toxicosis, etc.)
• Drugs - discontinue suspect drugs (corticosteroids, azathioprine, L-asparaginase, potassium bromide, organophosphates)
• Obesity - weight management long-term
• Most cases (~80-90%) are idiopathic

2. Fluid Therapy

Goals

• Correct dehydration
• Maintain pancreatic microcirculation
• Replace ongoing losses (vomiting, diarrhea)

Fluid Choice

• Isotonic crystalloids are first-line: Lactated Ringer's Solution (LRS) or 0.9% NaCl
• LRS is preferred by many clinicians as it is more physiologic; 0.9% NaCl may worsen hyperchloremic metabolic acidosis if used aggressively
• Colloids (hydroxyethyl starch) are reserved for hypooncotic states (low albumin <15-18 g/L) or refractory hypotension

Rate and Volume

• Calculate: Deficit + Maintenance + Ongoing losses
  • Deficit (L) = % dehydration x body weight (kg)
  • Replace deficit over 4-8 hours if no cardiac contraindication
  • Maintenance: ~2-3 mL/kg/hr in dogs
• Moderate fluid resuscitation is now preferred over aggressive resuscitation - fluid boluses (10-20 mL/kg over 15-30 min) should be given only in response to signs of hypovolemia (tachycardia, poor pulse quality, hypotension), mirroring human medicine evidence that moderate resuscitation avoids fluid overload complications

Monitoring

• Reassess hydration status every 4-8 hours
• Monitor for fluid overload: peripheral edema, pulmonary crackles, worsening respiratory effort
• Measure PCV/TP, urine output (target >1-2 mL/kg/hr), blood pressure

3. Analgesia

Mild to Moderate Pain

Severe Pain - CRI (Continuous Rate Infusion)

Adjuncts for Refractory or Opioid-Sparing Pain Control

• Ketamine CRI: 4 mg/kg IV bolus, then CRI (NMDA antagonist - reduces central sensitization)
• Lidocaine CRI: 2-4 mg/kg IV bolus, then 2-4 mg/kg/hr IV (use cautiously - assess cardiac status)
• Combined "MLK" (morphine-lidocaine-ketamine) CRI is commonly used in severe cases

Avoid NSAIDs - they worsen GI mucosal injury and can impair renal perfusion in a dehydrated patient.

4. Antiemetics

First-Line

• Maropitant (Cerenia) - NK-1 receptor antagonist; blocks central and peripheral emesis, may also reduce visceral pain and lung injury
  • 1 mg/kg SC or IV q24h (give IV slowly over 1-2 min)
  • Drug of choice; has additional visceral analgesic properties
• Ondansetron - 5-HT3 antagonist; add if maropitant alone insufficient
  • 0.5 mg/kg IV once, then q12-24h (or as a 6-hour infusion)

Second-Line (if above combination fails)

• Metoclopramide - dopamine D2 antagonist and prokinetic
  • Use cautiously; theoretically contraindicated due to dopaminergic effects, but clinically not clearly harmful
  • CRI: 1-2 mg/kg/24h IV infusion preferred over bolus dosing
  • Useful if gastroparesis/ileus is a component

Metoclopramide is not currently recommended as first-line by most experts given the superior efficacy of maropitant/ondansetron.

5. Nutritional Support

"NPO" is Obsolete

Current Standard: Early Enteral Nutrition (EEN)

• Begin as soon as vomiting is controlled (within 24-48 hours of admission)
• EEN reduces intestinal mucosal atrophy, prevents bacterial translocation, speeds return to voluntary intake, and improves GI tolerance

Diet Formulation

• Highly digestible, low-fat diet: target <20 g fat / 1000 kcal
• Commercial prescription GI or low-fat diets (e.g., Hill's i/d Low Fat, Royal Canin GI Low Fat)

Caloric Target

• Use Resting Energy Requirement (RER):
  • RER (kcal/day) = 70 x (BW in kg)^0.75
  • Example: 10 kg dog = 70 x 10^0.75 = ~394 kcal/day

Feeding Protocol (gradual reintroduction)

When Voluntary Intake Fails

• Nasoesophageal (NE) tube - easiest to place, no anesthesia needed; use liquid enteral diets; suitable for short-term use
• Esophagostomy (E-tube) - preferred for longer-term assisted feeding; requires brief anesthesia; allows use of blended food
• Parenteral nutrition (PN) - reserved as a last resort when enteral feeding is not tolerated or contraindicated (paralytic ileus, severe peritonitis); associated with higher complication rates than enteral feeding

Appetite Stimulants (adjuncts)

• Mirtazapine: 1.88 mg/dog (cats) or 0.5-1.5 mg/kg q24h (dogs)
• Capromorelin (Entyce): 3 mg/kg PO q24h - ghrelin receptor agonist licensed in dogs

6. Specific Pharmacologic Therapy: Fuzapladib Sodium (Panoquell-CA1)

• Mechanism: LFA-1 (Lymphocyte Function-Associated Antigen-1) antagonist - prevents neutrophil extravasation into the pancreatic tissue, reducing the inflammatory cascade, SIRS, and ARDS
• Dose: 0.4 mg/kg IV bolus over 15-60 seconds, q24h for 3 consecutive days
• Evidence: RCT (Steiner et al., JVIM 2023) showed significantly faster clinical improvement vs placebo
• Regulatory status: Licensed in Japan; FDA conditional approval in the US (Panoquell-CA1, Ceva Animal Health); not yet available in Europe (as of 2025)
• Adverse effects: Reported in some dogs - facial edema, anaphylaxis-like reactions, hypertension (some also seen in control group so unclear causal link)

7. Antibiotics

• Aspiration pneumonia
• GI bacterial translocation (septicemia signs: fever, left-shift neutrophilia, positive blood cultures)
• Infected pancreatic fluid collections or abscess (rare in dogs)
• Another concurrent bacterial infection

• Amoxicillin-clavulanate (broad-spectrum, good GI tract coverage)
• Fluoroquinolone + metronidazole (for suspected gram-negative/anaerobic translocation)
• Enrofloxacin (10 mg/kg IV or PO q24h) is often chosen for suspected septicemia

8. Proton Pump Inhibitors / Gastroprotectants

Routine PPIs increase risk of aspiration pneumonia if aspiration occurs and are not indicated in uncomplicated pancreatitis.

9. Plasma Transfusions

• Documented coagulopathy (DIC) - replace clotting factors
• Severe hypoalbuminemia (<15 g/L) contributing to edema - though colloids are often preferred
• Historically used to replenish alpha-2 macroglobulin (a protease inhibitor), but no controlled evidence supports routine use

10. Corticosteroids

• A single retrospective study suggested possible benefit in acute pancreatitis
• Not currently recommended for routine use pending further prospective data
• May be considered in immune-mediated forms of chronic pancreatitis

11. Managing Complications

Local Complications

Systemic Complications

12. Chronic / Recurrent Pancreatitis

• Immunosuppressive therapy: prednisolone or other immunosuppressants may be considered if immune-mediated etiology is suspected (based on histopathology showing lymphocytic inflammation)
• Long-term dietary management: strict low-fat diet (<10% fat DM basis), avoid table scraps
• Manage concurrent diseases: hypothyroidism, diabetes mellitus, hyperadrenocorticism
• Cobalamin (Vitamin B12) supplementation: if hypocobalaminemia is present (common with concurrent EPI or chronic GI disease)
• Enzyme supplementation: only if concurrent exocrine pancreatic insufficiency (EPI) develops

13. Monitoring Parameters

14. Surgical Indications (Rare)

• Septic peritonitis
• GI tract necrosis
• Infected pancreatic necrosis unresponsive to medical management
• Biliary obstruction not resolving medically
• Pancreatic fluid accumulation requiring drainage when aspiration is inadequate

Prognosis

• Mild to moderate: good prognosis with appropriate supportive care
• Severe / necrotizing: mortality rate 20-42%, higher with comorbidities (DM, renal disease, coagulopathy, SIRS, MODS)
• Prognostic markers: CRP trend, degree of azotemia, presence of DIC, SIRS criteria

Key Evidence Update (2024)

1. Tailored, moderate fluid therapy rather than aggressive resuscitation
2. Early enteral nutrition over NPO
3. Fuzapladib sodium as the first targeted therapy
4. Antibiotics only when specifically indicated
5. Corticosteroids and plasma not recommended routinely